Compare Recursion Pharmaceuticals Inc (RXRX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Block Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $2.91 (market cap $1.53B), while Block Inc trades at $79.5 (market cap $47.19B). The key difference: Block Inc is far larger — about 30.8× Recursion Pharmaceuticals Inc's market cap, and Block Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XYZ | |
|---|---|---|
Market Cap | $1.53B | $47.19B |
Sector | Health | Technology |
52-Week High | $6.79 | $81.81 |
52-Week Low | $2.84 | $49.04 |
Enterprise Value | $946.50M | $42.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Block (XYZ) trades at $79.72, down 0.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported mixed Q1 2026 earnings, beating expectations with $0.85 EPS versus $0.675 forecast, while revenue reached $24.19 billion in 2025. Recent news highlights include a $45 million settlement over Cash App fraud allegations and continued strength in Square and Cash App segments.
The stock offers 12% upside to the $89.53 consensus price target, supported by 74% analyst buy ratings. However, elevated P/E of 62.45 and declining net income margins from 12.01% to 5.39% pose valuation concerns. Key risks include rising credit losses and regulatory scrutiny, while AI integration and payment growth present long-term opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
